BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res 2021;149:1-61. [PMID: 33579421 DOI: 10.1016/bs.acr.2020.10.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Li H, Liang C, Kuang D, Huang G, Zhang M, Chen P, Zheng Q, Xu W, Ren J, Han X, Duan X. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma. Cancer Biol Ther 2023;24:2166335. [PMID: 36751709 DOI: 10.1080/15384047.2023.2166335] [Reference Citation Analysis]
2 Wang L, Yang Q, Zhou Q, Fang F, Lei K, Liu Z, Zheng G, Zhu L, Huo J, Li X, Peng S, Kuang M, Lin S, Huang M, Xu L. METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett 2023;559:216122. [PMID: 36898427 DOI: 10.1016/j.canlet.2023.216122] [Reference Citation Analysis]
3 Long F, Chen H, Li R, Lin Y, Han J, Guo J, Chen Y, Li C, Song P. Efficacy and Safety of HAIC alone VS. HAIC combined with Lenvatinib for Treatment of Advanced Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-2680076/v1] [Reference Citation Analysis]
4 Dong L, Zhou S, Bai X, He X. Construction of a prognostic model for HCC based on ferroptosis-related lncRNAs expression and its potential to predict the response and irAEs of immunotherapy. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1090895] [Reference Citation Analysis]
5 Wu D, Cai Q, Liu D, Zuo G, Li S, Liu L, Zheng J. Identification of molecular subtypes and prognostic signatures based on transient receptor potential channel-related genes to predict the prognostic risk of hepatocellular carcinoma: A review. Medicine (Baltimore) 2023;102:e33228. [PMID: 36897679 DOI: 10.1097/MD.0000000000033228] [Reference Citation Analysis]
6 Zhang J, Hu C, Xie X, Qi L, Li C, Li S. Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. Vaccines 2023;11:614. [DOI: 10.3390/vaccines11030614] [Reference Citation Analysis]
7 Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang J, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. bioRxiv 2023:2023. [PMID: 36945365 DOI: 10.1101/2023.03.05.531188] [Reference Citation Analysis]
8 Xu K, Xia P, Chen X, Ma W, Yuan Y. ncRNA-mediated fatty acid metabolism reprogramming in HCC. Trends Endocrinol Metab 2023:S1043-2760(23)00038-3. [PMID: 36890041 DOI: 10.1016/j.tem.2023.02.007] [Reference Citation Analysis]
9 Yang ZH, Wang SX. Exploring the Prognostic Features of Hepatocellular Carcinoma via Text Mining and Data Analysis. Mol Biol 2023. [DOI: 10.1134/s0026893323030160] [Reference Citation Analysis]
10 Meng GX, Yang CC, Yan LJ, Yang YF, Yan YC, Hong JG, Chen ZQ, Dong ZR, Li T. The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma. Heliyon 2023;9:e14307. [PMID: 36950649 DOI: 10.1016/j.heliyon.2023.e14307] [Reference Citation Analysis]
11 Zhao X, Wang E, Xu H, Zhang L. Stratifin promotes the growth and proliferation of hepatocellular carcinoma. Tissue and Cell 2023. [DOI: 10.1016/j.tice.2023.102080] [Reference Citation Analysis]
12 Liu Y, Qiao Y, Zhou M, Guo J, Lin Y, Li W, An C, Li C. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. Cancer Med 2023;12:5436-49. [PMID: 36254376 DOI: 10.1002/cam4.5366] [Reference Citation Analysis]
13 Xu Y, Xu X, Ni X, Pan J, Chen M, Lin Y, Zhao Z, Zhang L, Ge N, Song G, Zhang J. Gene-based cancer-testis antigens as prognostic indicators in hepatocellular carcinoma. Heliyon 2023;9:e13269. [PMID: 36950598 DOI: 10.1016/j.heliyon.2023.e13269] [Reference Citation Analysis]
14 Nevola R, Ruocco R, Criscuolo L, Villani A, Alfano M, Beccia D, Imbriani S, Claar E, Cozzolino D, Sasso FC, Marrone A, Adinolfi LE, Rinaldi L. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol 2023; 29(8): 1243-1260 [DOI: 10.3748/wjg.v29.i8.1243] [Reference Citation Analysis]
15 Caddeo C, Miglionico R, Rinaldi R, Nigro I, Lamorte D, Chiummiento L, Lupattelli P, Funicello M, D'Orsi R, Valenti D, Santoro V, Fadda AM, Bisaccia F, Vassallo A, Armentano MF. PEGylated Liposomes Loaded with Carbamate Inhibitor ANP0903 Trigger Apoptosis by Enhancing ER Stress in HepG2 Cancer Cells. Int J Mol Sci 2023;24. [PMID: 36901980 DOI: 10.3390/ijms24054552] [Reference Citation Analysis]
16 Eun JW, Ahn HR, Baek GO, Yoon MG, Son JA, Weon JH, Yoon JH, Kim HS, Han JE, Kim SS, Cheong JY, Kim BW, Cho HJ. Aberrantly Expressed MicroRNAs in Cancer-Associated Fibroblasts and Their Target Oncogenic Signatures in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36901700 DOI: 10.3390/ijms24054272] [Reference Citation Analysis]
17 Huang Q, Li J, Ma M, Lv M, Hu R, Sun J, Zhong X, Sun X, Feng W, Ma W, Zhang W, Zhan B, Han Z, Zhou X. High‑throughput screening identification of a small‑molecule compound that induces ferroptosis and attenuates the invasion and migration of hepatocellular carcinoma cells by targeting the STAT3/GPX4 axis. Int J Oncol 2023;62:42. [PMID: 36825585 DOI: 10.3892/ijo.2023.5490] [Reference Citation Analysis]
18 van Son KC, Verschuren L, Hanemaaijer R, Reeves H, Takkenberg RB, Drenth JPH, Tushuizen ME, Holleboom AG. Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2023;15. [PMID: 36831649 DOI: 10.3390/cancers15041308] [Reference Citation Analysis]
19 Duan Y, Hou X, Guo J, Li H, Cai L, Cheng L, Zhao W, Shao X, Du H, Diao Z, Li C. D-dimer for assessment of treatment response, and survival to drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2023;47:102096. [PMID: 36801385 DOI: 10.1016/j.clinre.2023.102096] [Reference Citation Analysis]
20 Cespiati A, Cinque F, Meroni M, Lombardi R, Dongiovanni P, Fracanzani AL. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. Biomedicines 2023;11. [PMID: 36831120 DOI: 10.3390/biomedicines11020586] [Reference Citation Analysis]
21 Chen G, Zhang C, Li D, Luo D, Liao H, Huang P, Wang N, Feng Y. HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma. Biomolecules 2023;13. [PMID: 36830729 DOI: 10.3390/biom13020360] [Reference Citation Analysis]
22 Chiang CF, Hsu YH, Hsieh WY, Liao TH, Chen CL, Chen YC, Liang PC, Wang SJ. IOP Injection, A Novel Superparamagnetic Iron Oxide Particle MRI Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase II Clinical Trial. J Magn Reson Imaging 2023. [PMID: 36773005 DOI: 10.1002/jmri.28645] [Reference Citation Analysis]
23 Jiang C, Sun XD, Qiu W, Chen YG, Sun DW, Lv GY. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy? Hepatobiliary Pancreat Dis Int 2023;22:7-13. [PMID: 36825482 DOI: 10.1016/j.hbpd.2022.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Wang M, Yang X, Meng Y, Jin Z, Cao J, Xiong L, Xiong Z. Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma. Int Immunopharmacol 2023;115:109660. [PMID: 36623412 DOI: 10.1016/j.intimp.2022.109660] [Reference Citation Analysis]
25 Zhang F, Lu J, Yang J, Dai Q, Du X, Xu Y, Zhang C. SNHG3 regulates NEIL3 via transcription factor E2F1 to mediate malignant proliferation of hepatocellular carcinoma. Immunogenetics 2023;75:39-51. [PMID: 36114381 DOI: 10.1007/s00251-022-01277-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Tsuchiya H, Shinonaga R, Sakaguchi H, Kitagawa Y, Yoshida K. NEAT1-SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines. Curr Issues Mol Biol 2023;45:1073-85. [PMID: 36826016 DOI: 10.3390/cimb45020071] [Reference Citation Analysis]
27 Özenver N, Efferth T. Identification of Prognostic and Predictive Biomarkers and Druggable Targets among 205 Antioxidant Genes in 21 Different Tumor Types via Data-Mining. Pharmaceutics 2023;15. [PMID: 36839749 DOI: 10.3390/pharmaceutics15020427] [Reference Citation Analysis]
28 Zhu S, Tang Z, Zou M, Tan T, Tang Y, Chen Y, Liang B, Xie D, Yang Y, Xie S, Xie G, Dong X, Liu T, Tang Y, Yang J. Correlation of DEPDC5 rs1012068 and rs5998152 Polymorphisms with Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Oncol 2023;2023:5957481. [PMID: 36733671 DOI: 10.1155/2023/5957481] [Reference Citation Analysis]
29 Xu Y, Ke S, Lu S, Wang C, Li Z, Feng Z, Yu H, Bai M, Qian B, Yin B, Li X, Hua Y, Jiang H, Ma Y. HLTF promotes hepatocellular carcinoma progression by enhancing SRSF1 stability and activating ERK/MAPK pathway. Oncogenesis 2023;12:2. [PMID: 36670110 DOI: 10.1038/s41389-023-00447-5] [Reference Citation Analysis]
30 Yao Y, Duan C, Chen Y, Hou Z, Cheng W, Li D, Wang Z, Xiang Y. Long Non-Coding RNA Detection Based on Multi-Probe-Induced Rolling Circle Amplification for Hepatocellular Carcinoma Early Diagnosis. Anal Chem 2023;95:1549-55. [PMID: 36598887 DOI: 10.1021/acs.analchem.2c04594] [Reference Citation Analysis]
31 Wang Y, Ma L, Xue P, Qin B, Wang T, Li B, Wu L, Zhao L, Liu X. Construction and Analysis of Hepatocellular Carcinoma Prognostic Model Based on Random Forest. Can J Gastroenterol Hepatol 2023;2023:6707698. [PMID: 36685007 DOI: 10.1155/2023/6707698] [Reference Citation Analysis]
32 Yu Q, Zhang H, Wang R, Deng T, Feng W, Zhang X, Wan C, Wang Q, Wang Y, Hu J, Liu Y, Yu Y. Identification of a Novel Costimulatory Molecule-Related Signature to Predict Prognostic Risk and Immunotherapy Response in Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-2390040/v1] [Reference Citation Analysis]
33 Sukaram T, Apiparakoon T, Tiyarattanachai T, Ariyaskul D, Kulkraisri K, Marukatat S, Rerknimitr R, Chaiteerakij R. VOCs from Exhaled Breath for the Diagnosis of Hepatocellular Carcinoma. Diagnostics (Basel) 2023;13. [PMID: 36673067 DOI: 10.3390/diagnostics13020257] [Reference Citation Analysis]
34 Stulpinas R, Zilenaite-Petrulaitiene D, Rasmusson A, Gulla A, Grigonyte A, Strupas K, Laurinavicius A. Prognostic Value of CD8+ Lymphocytes in Hepatocellular Carcinoma and Perineoplastic Parenchyma Assessed by Interface Density Profiles in Liver Resection Samples. Cancers (Basel) 2023;15. [PMID: 36672317 DOI: 10.3390/cancers15020366] [Reference Citation Analysis]
35 Duan T, Yang X, Kuang J, Sun W, Li J, Ge J, Zhang M, Cai X, Yu P, Yang J, Zhu X. ULK1 Depletion Protects Mice from Diethylnitrosamine-Induced Hepatocarcinogenesis by Promoting Apoptosis and Inhibiting Autophagy. J Hepatocell Carcinoma 2023;10:315-25. [PMID: 36874251 DOI: 10.2147/JHC.S399855] [Reference Citation Analysis]
36 Zhang H, Li C, Liao S, Tu Y, Sun S, Yao F, Li Z, Wang Z. PSMD12 promotes the activation of the MEK-ERK pathway by upregulating KIF15 to promote the malignant progression of liver cancer. Cancer Biol Ther 2022;23:1-11. [PMID: 36137220 DOI: 10.1080/15384047.2022.2125260] [Reference Citation Analysis]
37 Chen J, Sun M, Cui X, Zhang X. Ginsenoside compound K induces mitochondrial apoptosis in human hepatoma cells through Bclaf1-mediated modulation of ERK signaling. Food and Agricultural Immunology 2022;33:799-816. [DOI: 10.1080/09540105.2022.2134313] [Reference Citation Analysis]
38 Liu S, Jia L, Quan B, Rong G, Li M, Xie R, Cai Y, Bi Y, Han S. Coiled-Coil Domain-Containing Protein 45 Is a Potential Prognostic Biomarker and Is Associated with Immune Cell Enrichment of Hepatocellular Carcinoma. Dis Markers 2022;2022:7745315. [PMID: 36618966 DOI: 10.1155/2022/7745315] [Reference Citation Analysis]
39 Wu DH, Liao CY, Wang DF, Huang L, Li G, Chen JZ, Wang L, Lin TS, Lai JL, Zhou SQ, Qiu FN, Zhang ZB, Chen YL, Wang YD, Zheng XC, Tian YF, Chen S. Textbook outcomes of hepatocellular carcinoma patients with sarcopenia: A multicenter analysis. Eur J Surg Oncol 2022:S0748-7983(22)01355-5. [PMID: 36586787 DOI: 10.1016/j.ejso.2022.12.009] [Reference Citation Analysis]
40 Fencer MG, Davis CH, Liu J, Galan MA, Spencer KR. Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial. J Investig Med High Impact Case Rep 2022;10:23247096221129470. [PMID: 36541195 DOI: 10.1177/23247096221129470] [Reference Citation Analysis]
41 Gao B, Wang Y, Lu S. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment. Funct Integr Genomics 2022;23:6. [PMID: 36536232 DOI: 10.1007/s10142-022-00933-w] [Reference Citation Analysis]
42 Li H, Qin Y, Huang Y, Wang J, Ren B. SPAG5: the upstream protein of Wnt and the target of curcumin to inhibit hepatocellular carcinoma?. [DOI: 10.21203/rs.3.rs-2329095/v1] [Reference Citation Analysis]
43 Rutkin IO, Zhuikov VN, Moiseenko VE, Granov DA. Minimally invasive surgery for hepatocellular carcinoma. Ann hir gepatol 2022;27:23-30. [DOI: 10.16931/1995-5464.2022-4-23-30] [Reference Citation Analysis]
44 Li G, Xu S, Yang S, Wu C, Zhang L, Wang H. An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma. Front Genet 2022;13:1029576. [PMID: 36568382 DOI: 10.3389/fgene.2022.1029576] [Reference Citation Analysis]
45 Lei Wang, Manman Qiu, Lili Wu, Zexing Li, Xinyi Meng, Lu He, Bing Yang. Construction and validation of prognostic signature for hepatocellular carcinoma basing on hepatitis B virus related specific genes. Infect Agent Cancer 2022;17:60. [PMID: 36474267 DOI: 10.1186/s13027-022-00470-y] [Reference Citation Analysis]
46 Pan GQ, Yang CC, Shang XL, Dong ZR, Li T. The causal relationship between white blood cell counts and hepatocellular carcinoma: a Mendelian randomization study. Eur J Med Res 2022;27:278. [PMID: 36471350 DOI: 10.1186/s40001-022-00900-y] [Reference Citation Analysis]
47 Ali E, Trailin A, Ambrozkiewicz F, Liška V, Hemminki K. Activated Hepatic Stellate Cells in Hepatocellular Carcinoma: Their Role as a Potential Target for Future Therapies. Int J Mol Sci 2022;23. [PMID: 36499616 DOI: 10.3390/ijms232315292] [Reference Citation Analysis]
48 Santarsiero A, Pappalardo I, Rosa GM, Pisano I, Superchi S, Convertini P, Todisco S, Scafato P, Infantino V. Mitochondrial Role in Intrinsic Apoptosis Induced by a New Synthesized Chalcone in Hepatocellular Carcinoma Cells. Biomedicines 2022;10. [PMID: 36551876 DOI: 10.3390/biomedicines10123120] [Reference Citation Analysis]
49 Hou G, Xu W, Ding D, Tian T, Liu G, Yang Y, Liu H, Zhou W. Metabolome and transcriptome integration reveals metabolic profile of hepatocellular carcinoma. J Gastroenterol Hepatol 2022;37:2321-30. [PMID: 36208127 DOI: 10.1111/jgh.16024] [Reference Citation Analysis]
50 Yuan J, Liu Z, Wu Z, Yang J, Yang J. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma. International Immunopharmacology 2022;113:109411. [DOI: 10.1016/j.intimp.2022.109411] [Reference Citation Analysis]
51 Reis HC, Turk V. COVID-DSNet: A novel deep convolutional neural network for detection of coronavirus (SARS-CoV-2) cases from CT and Chest X-Ray images. Artif Intell Med 2022;134:102427. [PMID: 36462906 DOI: 10.1016/j.artmed.2022.102427] [Reference Citation Analysis]
52 Tucan P, Vaida C, Horvath D, Caprariu A, Burz A, Gherman B, Iakab S, Pisla D. Design and Experimental Setup of a Robotic Medical Instrument for Brachytherapy in Non-Resectable Liver Tumors. Cancers (Basel) 2022;14. [PMID: 36497325 DOI: 10.3390/cancers14235841] [Reference Citation Analysis]
53 Chan MH, Li CH, Chang YC, Hsiao M. Iron-Based Ceramic Composite Nanomaterials for Magnetic Fluid Hyperthermia and Drug Delivery. Pharmaceutics 2022;14. [PMID: 36559083 DOI: 10.3390/pharmaceutics14122584] [Reference Citation Analysis]
54 Song G, He T, Ji K, Duan Y, Zhang J, Hu G. SKA1/2/3 is a biomarker of poor prognosis in human hepatocellular carcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1038925] [Reference Citation Analysis]
55 Fei X, Liu S, Liu P, Wang X, Zhu C, Hou J, Cai J, Pan Y. Identification and validation of a potential key gene SGOL1 for poor prognosis in hepatocellular carcinoma based on a bioinformatics approach. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1043161] [Reference Citation Analysis]
56 Wu D, Cai Q, Liu D, Zuo G, Li S, Liu L, Zheng J. Identification of molecular subtypes and prognostic signatures based on transient receptor potential channel-related genes to predict the prognostic risk of hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2177604/v1] [Reference Citation Analysis]
57 Xu Y, Yu X, Zhang Q, He Y, Guo W. A novel classification of HCC basing on fatty-acid-associated lncRNA. Sci Rep 2022;12:18863. [PMID: 36344648 DOI: 10.1038/s41598-022-23681-0] [Reference Citation Analysis]
58 Li X, Jiang P, Li R, Wu B, Zhao K, Li S, Cai J. Analysis of cuproptosis in hepatocellular carcinoma using multi-omics reveals a comprehensive HCC landscape and the immune patterns of cuproptosis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1009036] [Reference Citation Analysis]
59 Qu N, Zhang X, Wu X, Zhou X, Deng Z, Ma L, Liu Y, Ge W, Jiang H, Xu L, Jiang H. Clinical implications of m6A‐related regulators YTHDF1 and YTHDF2 in hepatocellular carcinoma. Precision Medical Sciences 2022. [DOI: 10.1002/prm2.12085] [Reference Citation Analysis]
60 Peng L, Yan Q, Chen Z, Hu Y, Sun Y, Miao Y, Wu Y, Yao Y, Tao L, Chen F, Li H, Xu T. Research progress on the role of cholesterol in hepatocellular carcinoma. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175410] [Reference Citation Analysis]
61 Hassan M, Elzallat M, Aboushousha T, Elhusseny Y, El-ahwany E. MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma. Non-coding RNA Research 2022. [DOI: 10.1016/j.ncrna.2022.11.005] [Reference Citation Analysis]
62 Zhang T, Xu D, Yi Y, Wang Y, Cui Z, Chen X, Ma Q, Song F, Zhu B, Zhao Z, Cao J, He D, Chen X, Liu B. Chitosan-lactobionic acid-thioctic acid-modified hollow mesoporous silica composite loaded with carborane for boron neutron capture therapy of hepatocellular carcinoma. Materials & Design 2022;223:111196. [DOI: 10.1016/j.matdes.2022.111196] [Reference Citation Analysis]
63 Zhou Y, Gu H, Shao B, Zhang S, Pall H, Peixoto RD, Mok SRS, Zhu G. Glycolysis-related gene dihydrolipoamide acetyltransferase promotes poor prognosis in hepatocellular carcinoma through the Wnt/β-catenin and PI3K/Akt signaling pathways. Ann Transl Med 2022;10:1240. [PMID: 36544660 DOI: 10.21037/atm-22-5272] [Reference Citation Analysis]
64 Fan FS. Coffee reduces the risk of hepatocellular carcinoma probably through inhibition of NLRP3 inflammasome activation by caffeine. Front Oncol 2022;12:1029491. [DOI: 10.3389/fonc.2022.1029491] [Reference Citation Analysis]
65 Castillo-gonzález R, Valle-noguera A, Gomez-sánchez MJ, Xia P, Cruz-adalia A. Innate lymphoid cells type 3 in cancer. Front Immunol 2022;13:1033252. [DOI: 10.3389/fimmu.2022.1033252] [Reference Citation Analysis]
66 Kang Z, Jin K, Jing J, Wang TJ. The Value of MRI Combined with AFP, AFP-L3, GP73, and DCP in the Diagnosis of Early Primary Liver Cancer. Disease Markers 2022;2022:1-5. [DOI: 10.1155/2022/8640999] [Reference Citation Analysis]
67 An C, Yao W, Zuo M, Li W, Chen Q, Wu P. Pesudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transcatheter Arteial Chemoembolization.. [DOI: 10.21203/rs.3.rs-1911883/v1] [Reference Citation Analysis]
68 Ruch B, Wagler J, Kumm K, Zhang C, Katariya NN, Garcia-Saenz-de-Sicilia M, Giorgakis E, Mathur AK. Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future. Curr Oncol 2022;29:7537-51. [PMID: 36290870 DOI: 10.3390/curroncol29100593] [Reference Citation Analysis]
69 Sarkar D. Providing meaningful survival benefit to hepatocellular carcinoma patients: combination therapy of future. Hepatobiliary Surg Nutr 2022;11:779-81. [PMID: 36268238 DOI: 10.21037/hbsn-22-322] [Reference Citation Analysis]
70 Li Z, Gao H, Zhang X, Liu Q, Chen G. Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma: Prediction of stage I HCC prognosis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02496-3] [Reference Citation Analysis]
71 Cerrito L, Ainora ME, Mosoni C, Borriello R, Gasbarrini A, Zocco MA. Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy. Cancers 2022;14:4647. [DOI: 10.3390/cancers14194647] [Reference Citation Analysis]
72 Liu Y, Hu L, Liu Q, Ye J, Zhang J, Li T. miR-3651 Participates in the Growth Cycle of Hepatocellular Carcinoma Cells and Promotes the Malignant Metastasis via the PI3K/AKT/mTOR Signalling Pathway. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/5744999] [Reference Citation Analysis]
73 Tang C, Yu H, Zheng Y, Feng W, Shen J, Yang D. lncRNA TINCR Regulates Proliferation and Invasion of Hepatocellular Carcinoma Cells by Regulating the miR-375/ATG7 Axis. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/8132403] [Reference Citation Analysis]
74 Qiao Y, Yuan F, Wang X, Hu J, Mao Y, Zhao Z. Identification and validation of real hub genes in hepatocellular carcinoma based on weighted gene co-expression network analysis. Cancer Biomark 2022. [PMID: 36120772 DOI: 10.3233/CBM-220151] [Reference Citation Analysis]
75 Chen W, Zhu P, Xu H, Hou X, Guo C, Kolla J. The Association between Immune Subgroups and Gene Modules for the Clinical, Cellular, and Molecular Characteristic of Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/7253876] [Reference Citation Analysis]
76 Zhu Y, Huang G, Li S, Xiong H, Chen R, Zuo L, Liu H. CircSMARCA5: A key circular RNA in various human diseases. Front Genet 2022;13:921306. [DOI: 10.3389/fgene.2022.921306] [Reference Citation Analysis]
77 Qian B, Lin H, Lan T, Li M, Wu X, Lin S, Song Z, Shen S, Peng B. Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma. World J Surg Oncol 2022;20:252. [PMID: 35932027 DOI: 10.1186/s12957-022-02681-4] [Reference Citation Analysis]
78 Zhang Y, Li ZY, Shen QM, Tuo JY, Tan JY, Tan YT, Li HL, Xiang YB. A prospective cohort study of cigarette smoking, alcohol drinking and liver cancer incidence in Chinese men. J Dig Dis 2022;23:527-34. [PMID: 36208410 DOI: 10.1111/1751-2980.13136] [Reference Citation Analysis]
79 Ren F, Wang D, Zhang X, Zhao N, Wang X, Zhang Y, Li L. Cross Analysis of Genomic-Pathologic Features on Multiple Primary Hepatocellular Carcinoma. Front Genet 2022;13:846517. [DOI: 10.3389/fgene.2022.846517] [Reference Citation Analysis]
80 Chaomin W, Wenhao N, Jialei H, Ting Z, Honglei F, Zhuang H, Yichao W, Changsen B, Yueguo L. Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer. Cell Oncol (Dordr) 2022. [PMID: 35716259 DOI: 10.1007/s13402-022-00683-8] [Reference Citation Analysis]
81 Guang Y. Ligand-modified Nanomaterials for Specific Targeting of Hepatocellular Carcinoma. Journal of Modern Nanotechnology 2022;2. [DOI: 10.53964/jmn.2022004] [Reference Citation Analysis]
82 Mai RY, Bai T, Luo XL, Wu GB. Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy. BMC Gastroenterol 2022;22:261. [PMID: 35606690 DOI: 10.1186/s12876-022-02328-4] [Reference Citation Analysis]
83 Zhao D, Cao J, Zhang L, Zhang S, Wu S. Targeted Molecular Imaging Probes Based on Magnetic Resonance Imaging for Hepatocellular Carcinoma Diagnosis and Treatment. Biosensors 2022;12:342. [DOI: 10.3390/bios12050342] [Reference Citation Analysis]
84 Zhao Y, Yao J. The Biological Functions and Clinical Values of Exosomal Circular RNAs in Hepatocellular Carcinoma. Front Oncol 2022;12:885214. [PMID: 35530313 DOI: 10.3389/fonc.2022.885214] [Reference Citation Analysis]
85 Chen H, Wang Y, Xie Z, Zhang L, Ge Y, Yu J, Zhang C, Jia W, Ma J, Liu W. Application Effect of ICG Fluorescence Real-Time Imaging Technology in Laparoscopic Hepatectomy. Front Oncol 2022;12:819960. [PMID: 35463377 DOI: 10.3389/fonc.2022.819960] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Yang Y, Gao L, Chen J, Xiao W, Liu R, Kan H. Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma. Bioengineered 2022;13:9211-31. [PMID: 35436411 DOI: 10.1080/21655979.2022.2057896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Pecorelli A, Franceschi P, Braccischi L, Izzo F, Renzulli M, Golfieri R. MRI Appearance of Focal Lesions in Liver Iron Overload. Diagnostics 2022;12:891. [DOI: 10.3390/diagnostics12040891] [Reference Citation Analysis]
88 Chen X, Wang Z, Zhao X, Zhang L, Zhou L, Li X, Ge C, Zhao F, Chen T, Xie H, Cui Y, Tian H, Li H, Yao M, Li J. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. Oncogene 2022;41:2492-504. [PMID: 35314791 DOI: 10.1038/s41388-022-02273-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Liu Y, Zhang H, Han X, Xing X, M.a. B. Bioinformatics Methods Reveal the Biomarkers and the miRNA-mRNA Network in Hepatocellular Carcinoma. Journal of Healthcare Engineering 2022;2022:1-8. [DOI: 10.1155/2022/9963096] [Reference Citation Analysis]
90 Wu K, Travaline CE, Elliot L. Right Atrial Tumor Invasion: A Rare Presentation of Hepatocellular Carcinoma. Cureus. [DOI: 10.7759/cureus.22901] [Reference Citation Analysis]
91 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
92 Yang M, Qiu Y, Yang Y, Wang W. An Integrated Analysis of the Identified PRPF19 as an Onco-immunological Biomarker Encompassing the Tumor Microenvironment, Disease Progression, and Prognoses in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:840010. [DOI: 10.3389/fcell.2022.840010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Zhang Y, Zhang Y, Shi X, Li J, Wang L, Xie C, Wang Y. Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. Front Oncol 2022;12:836333. [DOI: 10.3389/fonc.2022.836333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Chen Q, Yang S, Zhang Y, Li B, Xu H, Zuo S, Yang Z. Identification of MAD2L1 as a Potential Biomarker in Hepatocellular Carcinoma via Comprehensive Bioinformatics Analysis. BioMed Research International 2022;2022:1-12. [DOI: 10.1155/2022/9868022] [Reference Citation Analysis]
95 刘 军. Research Progress of Immune Checkpoint Inhibitors in the Treatment of Primary Liver Cancer. ACM 2022;12:3360-3366. [DOI: 10.12677/acm.2022.124486] [Reference Citation Analysis]
96 Wan Q, Anugwom C, Desalegn H, Debes JD. Hepatocellular carcinoma in Hepatitis B and Human Immunodeficiency Virus coinfection in Africa: a focus on surveillance. Hepatoma Res 2022;8:39. [PMID: 36277115 DOI: 10.20517/2394-5079.2022.32] [Reference Citation Analysis]
97 Tian Y, Lu J, Qiao Y. A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma. Front Mol Biosci 2022;9:988323. [PMID: 36250026 DOI: 10.3389/fmolb.2022.988323] [Reference Citation Analysis]
98 Rong MH, Li JD, Zhong LY, Huang YZ, Chen J, Xie LY, Qin RX, He XL, Zhu ZH, Huang SN, Zhou XG. CCNB1 promotes the development of hepatocellular carcinoma by mediating DNA replication in the cell cycle. Exp Biol Med (Maywood) 2021;:15353702211049149. [PMID: 34743578 DOI: 10.1177/15353702211049149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Zhao J, Wang Y, Su H, Su L. Non-coding RNAs as biomarkers for hepatocellular carcinoma—A systematic review. Clinics and Research in Hepatology and Gastroenterology 2021;45:101736. [DOI: 10.1016/j.clinre.2021.101736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
100 Chu PY, Chan SH. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5295. [PMID: 34771459 DOI: 10.3390/cancers13215295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
101 Ghouraba MH, Masad RJ, Mpingirika EZ, Abdelraheem OM, Zeghlache R, Alserw AM, Amleh A. Role of NELF-B in supporting epithelial-mesenchymal transition and cell proliferation during hepatocellular carcinoma progression. Oncol Lett 2021;22:761. [PMID: 34539865 DOI: 10.3892/ol.2021.13022] [Reference Citation Analysis]
102 Gao C, Shen J, Chen W, Yao L, Liang X, Zhu R, Chen Z. Increased RBM12 expression predicts poor prognosis in hepatocellular carcinoma based on bioinformatics. J Gastrointest Oncol 2021;12:1905-26. [PMID: 34532138 DOI: 10.21037/jgo-21-390] [Reference Citation Analysis]
103 Xu XF, Yang XK, Song Y, Chen BJ, Yu X, Xu T, Chen ZL. Dysregulation of Non-coding RNAs mediates Cisplatin Resistance in Hepatocellular Carcinoma and therapeutic strategies. Pharmacol Res 2021;:105906. [PMID: 34543740 DOI: 10.1016/j.phrs.2021.105906] [Reference Citation Analysis]
104 Lu Z, Sun Z, Liu C, Shi X, Li R, Shao W, Zheng Y, Li Y, Song J. Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation: a retrospective cohort study. BMC Cancer 2021;21:751. [PMID: 34187430 DOI: 10.1186/s12885-021-08505-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Miao W, Nie P, Yang G, Wang Y, Yan L, Zhao Y, Yu T, Yu M, Wu F, Rao W, Wang Z. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur J Nucl Med Mol Imaging 2021. [PMID: 33813592 DOI: 10.1007/s00259-021-05328-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]